We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Sicor and BioGeneriX to Develop Generic Biopharmaceuticals

By Biotechdaily staff writers
Posted on 31 Jul 2003
An agreement to jointly develop and market a recombinant protein pharmaceutical has been announced by Sicor, Inc. More...
(Irvine, CA, USA; www.sicor.com) and BioGeneriX AG (Mannheim, Germany; www.biogenerix.com).

The pharmaceutical will be manufactured and produced by Sicor and marketed in Europe by BioGeneriX's parent company (ratiopharm), following regulatory approval. BioGeneriX will receive a royalty on Sicor's sales in North and Central America. Financial terms were not disclosed.

Sicor is a multinational pharmaceutical company focused on generic injectable pharmaceuticals and generic biopharmaceuticals, concentrating on products and technologies that present significant barriers to entry or that offer first-to-market opportunities. BioGeneriX specializes in the development of biopharmaceutical drugs with known mode of actions and established markets for ratiopharm and other global partners.

"This collaboration provides access to European markets through the BioGeneriX clinical development program and ratiopharm's sales force while simultaneously giving Sicor the potential to expedite its entry into North American biopharmaceutical markets,” said Marvin Samson, president and CEO of Sicor.





Related Links:
Sicor
BioGeneriX

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.